"I doubt it hits $4 early on if ANCHOR is granted"
sts...IHBTD...IMHO the share price will jump to over $10 if the FDA grants the SPA or comes with the sNDA....It was the cancellation of the SPA and the people who were privy to that info before the AdComm that laid this stock low, but that changes if the 35 million cohort is breached. Remember this is a cohort for which there is no other competitors, and the insurance companies are not going to be able to brush aside scripts as they do now.
Also choose not to believe that Amarin brought all this on themselves by some trivial foolish insistence..
Your kidding right? Come on STS! This can go to $5-$7 with out flinching! The problem with Marine has not been the drug, but sales force and insurance carriers, tier coverage of TG's >500 range, approving Anchor will be like opening Pandora's box or jar.
Vascepa's label is more restricted than Lovaza's was? Why, you would have to ask the FDA.
Market Data 
Markets 
AI
